FIGURE 3.

Abemaciclib in combination with gilteritinib inhibits Rb and AKT pathways (A) A549, H1650 cells were treated by 1 μM abemaciclib, or 150 nM gilteritinib alone, or their combination for 72 h, and Western blot was used to determine the expressions of cyclin D1, CDK2, CDK4, p-AKT (ser473), AKT, p-Rb (ser807/811, ser780) and Rb (B) A549 and H1650 cells were treated by gilteritinib (150 nM) alone, or combined with abemaciclib for increasing time points, and Western blot was used to determine the expressions of p-AKT (ser473) and AKT, GAPDH was used as a loading control.